Astrazeneca (AZN) Goodwill & Intangibles (2016 - 2026)

Astrazeneca has reported Goodwill & Intangibles over the past 18 years, most recently at $58.1 billion for Q1 2026.

For Q1 2026, Goodwill & Intangibles fell 0.99% year-over-year to $58.1 billion; the TTM value through Mar 2026 reached $58.1 billion, down 0.99%, while the annual FY2025 figure was $59.1 billion, 1.52% up from the prior year.
Goodwill & Intangibles for Q1 2026 was $58.1 billion at Astrazeneca, down from $59.1 billion in the prior quarter.
Over five years, Goodwill & Intangibles peaked at $61.2 billion in Q1 2022 and troughed at $2.4 billion in Q4 2023.
A 5-year average of $55.8 billion and a median of $59.1 billion in 2022 define the central range for Goodwill & Intangibles.
Biggest five-year swings in Goodwill & Intangibles: tumbled 95.95% in 2023 and later skyrocketed 2331.16% in 2024.
Year by year, Goodwill & Intangibles stood at $59.1 billion in 2022, then tumbled by 95.95% to $2.4 billion in 2023, then skyrocketed by 2331.16% to $58.2 billion in 2024, then rose by 1.52% to $59.1 billion in 2025, then decreased by 1.67% to $58.1 billion in 2026.
Business Quant data shows Goodwill & Intangibles for AZN at $58.1 billion in Q1 2026, $59.1 billion in Q4 2025, and $59.4 billion in Q3 2025.

Peer Comparison